Perelman School of Medicine at the University of Pennsylvania

Penn Institute for Immunology

Jan Joseph Melenhorst

faculty photo
Adjunct Associate Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations

Contact information
SPE South Tower, Rm. 9-105,
3400 Civic Center Boulevard, Blg. 421
Philadelphia, PA 19104-5156
Office: 215.573.6852
Lab: N/A
BSc (Biology, Geography, Associate Professor in Continuing Education)
Moller Institute, 1988.
MS (Medical Biology)
Nijmegen Katholic University, 1991.
PhD (Immunology)
Leiden University, 1998.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

As a translational immunologist my interest is in improving the potency and safety of adoptive immunogene therapy via correlative studies and product/process development. My translational interest also lies in streamlining the immunogene manufacturing process while maintaining or improving product potency.

Description of Other Expertise

Immunology of human allogeneic hematopoietic stem cell transplantation.

Description of Research Expertise

My expertise is in human T cell immunology and immunogene therapy, understanding and improving the anti-tumor efficacy of gene-engineered T cells for the treatment of cancers.

Selected Publications

O'Rourke DM, Melenhorst JJ, Nasrallah MP, Desai A, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. AAAS, 9(399): eaaa0984, July 2017.

Elise A. Chong, J. Joseph Melenhorst, Simon F. Lacey, David E. Ambrose, Vanessa Gonzalez, Bruce Levine, Carl H. June, and Stephen J. Schuster: PD-1 Blockade Modulates Chimeric Antigen Receptor (CAR) Modified T Cells and Induces Tumor Regression: Refueling the CAR. Blood. Blood, 129(8): 1039-1041, Feb 2017.

Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT: Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med 45(2), Feb 2017.

Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill S.: Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia 31(1): 246-248, Jan 2017.

Mala K. Talekar, George E. Hucks, Shannon L. Maude, Nicholas A Kawchak, Laura S Motley, David M. Barrett, Simon F. Lacey, Bruce L. Levine, Jan J. Melenhorst, Pamela A. Shaw, Colleen A. Callahan, Claire M White, Christine Barker, Diane Baniewicz, Mark Duckworth, Richard Aplenc, David T Teachey, Carl H. June, Stephan A Grupp and Susan R Rheingold. : Chimeric Antigen Receptor (CAR)-Modified T Cells (CTL019) Induce Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. Pediatric Blood & Cancer 2017.

Mala K. Talekar, Shannon L. Maude, George E. Hucks, Laura S. Motley, Colleen A. Callahan, Claire M. White, Diane Baniewicz, David M. Barrett, Susan R. Rheingold, Simon F. Lacey, Bruce L. Levine, Jan J. Melenhorst, David T. Teachey, Carl H. June, and Stephan A. Grupp : Chimeric Antigen Receptor (CAR)-Modified T Cells (CAR-T) Induce Potent and Durable Responses In Children With Non-CNS Extramedullary Relapse Of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (ALL) Journal of Clinical Oncology 2017.

Saar I Gill MD PhD*, Noelle V Frey MD MS, Elizabeth O Hexner MD, Simon F Lacey PhD, J Joseph Melenhorst PhD, John Byrd MD, Susan Metzger RN, Taylor Marcus, Wei-Ting Hwang PhD, Carl H June MD and David L Porter MD.: CD19-targeted chimeric antigen receptor (CAR) T cells combined with ibrutinib in adults with chronic lymphocytic leukemia. Journal of CLinical Oncology 2017.

Rebecca H. Kim, Gabriella Plesa, Whitney L. Gladney, Bruce L. Levine, Farzana Nazimuddin, [TCSL molecular team member], Simon F. Lacey, Jan J. Melenhorst, Gregory L. Beatty : Chimeric antigen receptor (CAR) T cells induce clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer Journal of Clinical Oncology 2017.

Ellebrecht CT, Secreto A, Mao X, Melenhorst JJ, Lacey SF, Zhou Y, Milone MC, Payne AS : Temporally controlled B cell depletion with universal chimeric antigen receptor (CAR) T cells for pemphigus vulgaris (PV) therapy Journal of Immunology 2017.

George E. Hucks, David M. Barrett, Susan R. Rheingold, Richard Aplenc, David T. Teachey, Colleen Callahan, Diane Baniewicz, Claire White, Mala Talekar, Pamela A. Shaw, Jennifer L. Brogdon, Regina Young, John Scholler, Katherine T. Marcucci, Bruce L. Levine, Noelle Frey, David L. Porter, Simon F. Lacey, Jan J. Melenhorst, Carl H. June, Stephan A. Grupp, Shannon L. Maude : Humanized Chimeric Antigen Receptor (CAR)-modified T cells Targeting CD19 Induce Remissions in Children and Young Adults with Relapsed/Refractory Lymphoblastic Leukemia/Lymphoma Cytotherapy 2017.

back to top
Last updated: 10/26/2017
The Trustees of the University of Pennsylvania